Spots Global Cancer Trial Database for StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
Official Title: Single-Center, Open Label, Randomized Trial Comparing StemRegenin-1 Expanded Versus Unmanipulated Umbilical Cord Blood Transplantation In Patients With High-Risk Malignancy
Study ID: NCT02765997
Study Description
Brief Summary: This is an open label, interventional, randomized phase II trial comparing StemRegenin-1 (SR-1) cultured umbilical cord blood (experimental arm) to unmanipulated umbilical cord blood (standard of care arm) transplantation after a myeloablative CY/FLU/TBI conditioning. A 2:1 randomization will be employed with a higher chance of being assigned to the experimental arm.
Detailed Description:
Eligibility
Minimum Age: 2 Years
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Contact Details
Name: John Wagner, MD
Affiliation: University of Minnesota
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
